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Abstract 
 
To develop PET tracers for imaging of Alzheimer’s disease, new carbon-11 labeled potent and 
selective PDE5 inhibitors have been synthesized. The reference standards (5) and (12), and their 
corresponding desmethylated precursors (6) and (13) were synthesized from methyl 2-amino-5-
bromobenzoate and (4-methoxyphenyl)methanamine in multiple steps with  2%, 1%, 1% and 
0.2% overall chemical yield, respectively. The radiotracers ([11C]5) and ([11C]12) were prepared 
from their corresponding precursors 6 and 13 with [11C]CH3OTf through O-11C-methylation and 
isolated by HPLC combined with SPE in 40-50% radiochemical yield, based on [11C]CO2 and 
decay corrected to EOB. The radiochemical purity was >99%, and the molar activity (Am) at 
EOB was in a range of 370-740 GBq/µmol. 
 
Keywords: Phosphodiesterase 5 (PDE5); Carbon-11 labeled PDE5 inhibitors; Radiosynthesis; 
Positron emission tomography (PET); Alzheimer’s disease (AD). 
 
 
1. Introduction 
 
Phosphodiesterases (PDEs) are a superfamily of enzymes, consisting of 11 families, that 
inactivate the second messenger molecules cyclic guanosine monophosphate (cGMP) and cyclic 
adenosine monophosphate (cAMP), which regulate the extracellular signal transduction and 
affect fundamental intracellular processes (Andrés et al., 2012; Fiorito et al., 2017; Schröder et 
al., 2016). Therefore, PDEs modulate various biological processes in both central nervous system 
(CNS) and peripheral tissues, and are associated with neurological, oncological and 
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cardiovascular diseases (Das et al., 2015). PDE has become an attractive therapeutic target, and 
many PDE inhibitors have been developed for the treatment of PDE-related diseases. In recent 
years, there has been tremendous interest in identifying new clinical uses of PDE inhibitors in 
Alzheimer’s disease (AD) due to the lack of effective treatments for AD (García-Osta et al., 
2012). The continued failure to find effective therapies for AD based on amyloid (Aβ) 
hypothesis and tau hypothesis has led researchers to search for new AD management/treatment 
strategies, and PDEs are promising non-Aβ related candidate targets (Sallustio et al., 2016). 
Indeed, both PDE4 and PDE5 inhibitors have been found to effectively restore memory function 
in animal models of AD (García-Osta et al., 2012; Cumming, 2016). Consequently PDEs have 
become interesting imaging targets in AD, as the development of imaging agents parallels the 
drug development process (Agdeppa and Spilker, 2009). Advanced biomedical imaging 
technique positron emission tomography (PET) is a promising modality for AD, and significant 
advances have occurred in this field of molecular imaging (Frisoni et al., 2017; Johnson et al., 
2012). There is a growing interest in design and evaluation of new PET radiotracers for in vivo 
imaging of PDEs including PDE2, PDE4, PDE5, PDE7 and PDE10 (Andrés et al., 2012; 
Schröder et al., 2016). In this project of new tracer development, we focus on PDE5 as target, 
because there are strong preclinical evidences suggesting that PDE5 may serve as a clinically 
relevant biomarker and a disease-relevant drug/imaging agent target in AD (Liu et al., 2016; 
Wenzel et al., 2019). Several PDE5 radioligands have been developed, and representative 
carbon-11 and fluorine-18 labeled PDE5 inhibitors with an IC50 value < 1 nM are shown in 
Figure 1, however, so far no successful detection of PDE5 in the brain for quantification of its 
expression or occupancy has been reported (Chekol et al., 2014; Schröder et al., 2016). This 
might result from the not high enough inhibitory activity and selectivity of PDE5 radioligands. 
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The PDE5 expression in the brain is low with only nanomolar density, and thus, a radioligand 
with at least subnanomolar PDE5 potency is needed for quantification of this enzyme in brain, 
but the available PDE5 radioligands only have nanomolar grade IC50 values (Chekol et al., 2014; 
Cumming, 2016; Schröder et al., 2016). Obviously an ideal PDE5 radioligand that can be used in 
the clinical setting to study PDE5 expression levels in AD remains to be discovered. Recently a 
novel series of naphthyridine and 1H-pyrroloquinolinone analogs have been developed as potent 
PDE5 inhibitors with picomolar potency for potential treatment of AD, and the excellent lead 
compounds, 2-acetyl-10-((3-chloro-4-methoxybenzyl)amino)-1,2,3,4-
tetrahydrobenzo[b][1,6]naphthyridine-8-carbonitrile (5) and 9-((3-chloro-4-
methoxybenzyl)amino)-2-ethyl-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-b]quinoline-7-carbonitrile 
(12), exhibited extremely high potency and excellent selectivity with IC50 0.056 nM (PDE5A1), 
30.1 nM (PDE6C), selectivity (PDE6C/PDE5A1) 537; and 0.059 nM (PDE5A1), 6.6 nM 
(PDE6C), selectivity (PDE6C/PDE5A1) 112; respectively (Fiorito et al., 2017). These two 
compounds have the combination of favorable in vitro activity to PDE5, and O-methyl positions 
amenable to labeling with carbon-11, therefore, their carbon-11 labeled radioligands are 
expected to have high specific binding. Here, we report the design, synthesis and labeling of 
carbon-11 labeled PDE5 inhibitors, 2-acetyl-10-((3-chloro-4-[11C]methoxybenzyl)amino)-
1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine-8-carbonitrile ([11C]5) and 9-((3-chloro-4-
[11C]methoxybenzyl)amino)-2-ethyl-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-b]quinoline-7-
carbonitrile ([11C]12)  (Figure 1), as new potential PET radiotracers for imaging of AD. 
 
Insert Figure 1 about here 
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2. Results and discussion 
 
2.1. Chemistry 
 
Synthesis of the reference standard 5 and its desmethylated precursor 2-acetyl-10-((3-chloro-4-
hydroxybenzyl)amino)-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine-8-carbonitrile (6) is 
indicated in Scheme 1.  Compound 5 was synthesized in multiple steps according to the reported 
procedures (Fiorito et al., 2017; Landry et al., 2015; Schroeder et al., 2014; Snieckus et al., 1972; 
Yu et al., 2003). The desmethylation of compound 5 with BBr3 in CH2Cl2 (Aiello et al., 2012; 
Waghmode et al., 2013) generated the precursor 6 in 30% yield, which is a new compound.      
 
Insert Scheme 1 about here 
 
Synthesis of the reference standard 12 and its desmethylated precursor 9-((3-chloro-4-
hydroxybenzyl)amino)-2-ethyl-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-b]quinoline-7-carbonitrile 
(13) is depicted in Scheme 2. Likewise, compound 12 was synthesized in multiple steps 
according to the reported procedures (Fiorito et al., 2017; Landry et al., 2015). Similarly, the 
desmethylation of compound 12 with BBr3 in CH2Cl2 (Aiello et al., 2012; Waghmode et al., 
2013) gave a new compound 13 in 20% yield.    
 
Insert Scheme 2 about here 
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2.2. Radiochemistry 
 
Synthesis of the radiotracers [11C]5 and [11C]12 is shown in Scheme 3. Desmethylated precursor 
6 or 13 underwent O-11C-methylation (Gao et al., 2018; Wang et al., 2018) using the reactive 
11C-methylating agent [11C]methyl triflate ([11C]CH3OTf) (Jewett, 1992; Mock et al., 1999) in 
acetonitrile at 80 °C under basic conditions (2 N NaOH). The product was isolated by semi-
preparative reversed-phase (RP) high performance liquid chromatography (HPLC) with a C-18 
column, and then concentrated by solid-phase extraction (SPE) (Wang et al., 2011, 2012a) with a 
disposable C-18 Light Sep-Pak cartridge to produce the corresponding pure radiolabeled 
compound [11C]5 or [11C]12 in 40-50%  radiochemical yield, decay corrected to end of 
bombardment (EOB), based on [11C]CO2. 
 
Insert Scheme 3 about here 
 
The radiosynthesis was performed in a home-built automated multi-purpose 11C-radiosynthesis 
module (Mock et al., 2005a,b; Wang et al., 2012b). Our radiosynthesis module facilitated the 
overall design of the reaction, purification and reformulation capabilities in a fashion suitable for 
adaptation to preparation of human doses. The radiosynthesis includes three stages: 1) labeling 
reaction; 2) purification; and 3) formulation. The overall synthesis time was 35-40 min from 
EOB. Our module is also designed to allow in-process measurement of 11C-tracer molar activity 
(Am, GBq/µmol at EOB) using semi-preparative RP-HPLC (Mock et al., 2005a). At the end of 
synthesis (EOS), the Am of 11C-tracer was determined again by analytical RP-HPLC, calculated, 
decay corrected to EOB, and based on [11C]CO2. Both semi-preparative and analytical RP-HPLC 
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methods gave similar Am values. The Am of [11C]5 and [11C]12 at EOB was in a range of 370-740 
GBq/µmol. The general method to increase the Am of 11C-tracer produced in our radiochemistry 
facility has been detailed in our previous work (Gao et al., 2018).      
 
Chemical purity and radiochemical purity were determined by analytical HPLC (Zheng and 
Mock, 2005). A representative analytical RP-HPLC chromatographic profile for the radiotracers 
[11C]5 and [11C]12, Radio-HPLC (A) and UV-HPLC (B) traces for [11C]5; Radio-HPLC (C) and 
UV-HPLC (D) traces for [11C]12, is shown in Figure 2. The radiochemical purity of [11C]5 or 
[11C]12 was >99% determined by radio-HPLC through γ-ray (PIN diode) flow detector as 
indicated in Figure 2, A or C. The chemical purity of [11C]5 or [11C]12 was simultaneously 
determined by UV-HPLC through UV flow detector as indicated in Figure 2, B or D. The minor 
impurities included its corresponding labeling precursor 6 or 13 and a few unknown UV peaks 
from the saline used in tracer formulation after HPLC-SPE purification. However, there is no 
chemical purity of the radiotracer release limit in PET tracer production, because the 
radiosynthesis is a micro-scale synthesis, and the radiotracer prepared is very trace amount. For 
non-UV active volatile organic impurities were analyzed and determined by a gas 
chromatography (GC) equipped with a capillary column and flame ionization detector (FID), and 
the results met all of the established quality control (QC) criteria.     
 
Insert Figure 2 about here   
 
 
3. Experimental 
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3.1. General 
 
All commercial reagents and solvents were purchased from Sigma-Aldrich and Fisher Scientific, 
and used without further purification. [11C]CH3OTf was prepared according to a literature 
procedure (Mock et al., 1999). Melting points were determined on WRR apparatus and were 
uncorrected. 1H and 13C NMR spectra were recorded on a Bruker Avance II 400 or 600 MHz 
NMR Fourier transform spectrometer at 400, 600 or 100 MHz, respectively. Chemical shifts (δ) 
are reported in parts per million (ppm) relative to an internal standard tetramethylsilane (TMS, δ 
0.0) (1H NMR) and to the solvent signal (13C NMR), and coupling constants (J) are reported in 
hertz (Hz).  Liquid chromatography-mass spectra (LC-MS) analysis was performed on AB Sciex 
4000Q Trap instrument, consisting of an 1100 series HPLC connected to a diode array detector 
and a 1946D mass spectrometer configured for positive-ion/negative-ion electrospray ionization 
(ESI). The high resolution mass spectra (HRMS) were obtained using a Waters/Micromass LCT 
Classic spectrometer. Chromatographic solvent proportions are indicated as volume : volume 
ratio. Thin-layer chromatography (TLC) was run using HS silica gel GF254 uniplates (5 × 10 
cm2).  Plates were visualized under UV light. Normal phase flash column chromatography was 
carried out on Combiflash Rf 150 silica gel 60 (300-400 mesh) with a forced flow of the 
indicated solvent system in the proportions described below. All moisture- and air-sensitive 
reactions were performed under a positive pressure of nitrogen maintained by a direct line from a 
nitrogen source. Analytical RP HPLC was performed using a Prodigy (Phenomenex) 5 µm C-18 
column, 4.6 × 250 mm, mobile phase 65% CH3CN/35% 4.0 mM CH3COONa, flow rate 1.0 
mL/min; UV (254 nm) and γ-ray (PIN diode) flow detectors. Semi-preparative RP HPLC was 
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performed using a Prodigy (Phenomenex) 5 µm C-18 column, 10 × 250 mm; 70% CH3CN:30% 
H2O mobile phase; 4 and 5 mL/min flow rate for [11C]5 and [11C]12, respectively; UV (254 nm) 
and γ-ray (PIN diode) flow detectors. C18 Light Sep-Pak cartridges were obtained from Waters 
Corporation (Milford, MA).  Sterile Millex-FG 0.2 µm filter units were obtained from Millipore 
Corporation (Bedford, MA).   
 
3.2. (3-Chloro-4-methoxyphenyl)methanamine (1) 
 
A white solid, mp 201.2-201.5 °C. 1H NMR (600 MHz, CD3OD): δ 7.54 (d, J = 2.4 Hz, 1H), 
7.42 (dd, J = 8.4, 2.4 Hz, 1H), 7.15 (d, J = 8.4 Hz, 1H), 4.08 (s, 2H), 3.92 (s, 3H). LC-MS (ESI, 
m/z): Calcd for C8H11ClNO ([M+H]+) 172.05, found: 172.06. 
 
3.3. Methyl 2-amino-5-cyanobenzoate (2) 
 
A pale yellow solid, mp 131.1-131.9 °C. 1H NMR (600 MHz, CDCl3): δ 8.19 (d, J = 1.8 Hz, 
1H), 7.45 (dd, J = 9.0, 1.8 Hz, 1H), 6.67 (d, J = 9.0 Hz, 1H), 6.30 (br s, 2H), 3.90 (s, 3H). LC-
MS (ESI, m/z): Calcd for C9H9N2O2 ([M+H]+) 177.06, found: 177.00.  
 
3.4. 2-Amino-5-cyanobenzoic acid (3) 
 
An off-white solid, mp 265.3-266.5 °C. 1H NMR (600 MHz, CD3OD): δ 8.14 (d, J = 2.4 Hz, 
1H), 7.46 (dd, J = 9.0, 2.4 Hz, 1H), 6.82 (d, J = 9.0 Hz, 1H), 4.88 (br s, 2H). LC-MS (ESI, m/z): 
Calcd for C8H7N2O2 ([M+H]+) 163.05, found: 163.10. 
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3.5. 2-Acetyl-10-chloro-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine-8-carbonitrile (4) 
 
A yellow solid, mp 180.2-181.5 °C. 1H NMR (400 MHz, CDCl3) (mixture of rotamers): δ 8.63 
(d, J = 1.6 Hz, 1H), 8.11-8.16 (m, 1H), 7.88-7.93 (m, 1H), 5.05 and 4.93 (2 s, 2H), 4.06 and 3.94 
(2 t, J = 6.0 Hz, 2H), 3.33 and 3.27 (2 t, J = 6.0 Hz, 2H), 2.32 and 2.30 (2 s, 3H). HRMS (ESI, 
m/z): Calcd for C15H13ClN3O ([M+H]+) 286.0742, found: 286.0739.  
 
3.6. 2-Acetyl-10-((3-chloro-4-methoxybenzyl)amino)-1,2,3,4-tetrahydrobenzo[b][1,6] 
naphthyridine-8-carbonitrile (5) 
 
Light yellow oil. 1H NMR (400 MHz, CDCl3) (mixture of rotamers): δ 8.42-8.47 (m, 1H), 7.96-
8.02 (m, 1H), 7.73-7.78 (m, 1H), 7.35-7.42 (m, 1H), 7.17-7.24 (m, 1H), 6.94 (d, J = 8.4 Hz, 1H), 
4.98 (m, 1H), 4.77 (s, 2H), 4.68 (d, J = 5.6Hz, 2H), 3.92 (s, 3H), 3.84 (t, J = 6.0 Hz, 2H), 3.23 
and 3.17 (2 t, J = 6.0 Hz, 2H), 2.23 (s, 3H). HRMS (ESI, m/z): C23H22ClN4O2 ([M+H]+) 
421.1426, found: 421.1432. 
 
3.7. 2-Acetyl-10-((3-chloro-4-hydroxybenzyl)amino)-1,2,3,4-tetrahydrobenzo[b][1,6] 
naphthyridine-8-carbonitrile (6) 
 
To a stirred solution of compound 5 (50 mg, 0.12 mmol) in CH2Cl2 (3 mL), BBr3 (60 μL, 0.6 
mmol) was added slowly at 0 ºC, and the reaction was continued at 0 ºC for 12 h. The reaction 
mixture was poured into ice water (10 mL), and then CH2Cl2 was removed under reduced 
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pressure. The resulted aqueous solution was extracted with EtOAc (3 × 20 mL), and the 
combined organic layer was washed with water, brine, dried over anhydrous Na2SO4 and filtered. 
The organic solution was evaporated under vacuum, and the resulted crude product was purified 
by silica gel column chromatography with CH2Cl2/MeOH (100:1 to 10:1) as eluent to afford 6 as 
a light yellow solid (15 mg, 30%), mp 114.1-115.8 °C. 1H NMR (400 MHz, CD3OD) (mixture of 
rotamers): δ 8.66 (d, J = 16.0 Hz, 1H), 7.90-7.95 (m, 1H), 7.81-7.86 (m, 1H), 7.33-7.40 (m, 1H), 
7.13-7.17 (m, 1H), 6.88-6.95 (m, 1H), 4.85 and 4.75 (2 s, 2H), 4.74 (s, 2H), 3.90-3.93 (m, 2H), 
3.21 and 3.11 (2 t, J = 6.4 Hz, 2H), 2.25 (s, 2H), 2.00 (d, J = 8.0 Hz, 3H). 13C NMR (100 MHz, 
CD3OD) (mixture of rotamers): δ 169.14, 168.89, 159.88, 152.48, 149.44, 149.34, 148.91, 
148.83, 132.23, 131.95, 130.25, 129.71, 129.12, 128.88, 127.26, 127.04, 120.13, 119.98, 119.76, 
117.12, 117.02, 113.88, 113.16, 106.30,106.22, 50.10, 45.08, 43.27, 33.77, 33.14, 21.84, 21.76. 
HRMS (ESI, m/z): C22H20ClN4O2 ([M+H]+) 407.1269, found: 407.1273. 
 
3.8. 2,4-Dioxo-1,4-dihydro-2H-benzo[d][1,3]oxazine-6-carbonitrile (7) 
 
A light yellow solid, mp 269.6-271.3 °C. 1H NMR (400 MHz, CD3OD): δ 8.36 (d, J = 2.0 Hz, 
1H), 8.00 (dd, J = 8.4, 2.0 Hz, 1H), 7.26 (d, J = 8.4 Hz, 1H). LC-MS (ESI, m/z): Calcd for 
C9H5N2O3 ([M+H]+) 189.02, found: 188.10. 
  
3.9. Methyl 6-cyano-2-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate (8) 
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A yellow solid, mp 300 °C (Dec.). 1H NMR (400 MHz, DMSO-d6): δ 12.31 (br s, 1H), 8.42 (s, 
1H), 8.04 (d, J = 8.8 Hz, 1H), 7.69 (d, J = 8.8 Hz, 1H), 3.81 (s, 3H), 2.44 (s, 3H). LC-MS (ESI, 
m/z): Calcd for C13H11N2O3 ([M+H]+) 243.07, found: 243.10. 
 
3.10. Methyl 4-chloro-6-cyano-2-methylquinoline-3-carboxylate (9) 
A white solid, mp 157.2-158.3 °C. 1H NMR (400 MHz, CDCl3): δ 8.66 (s, 1H), 8.17 (d, J = 8.4 
Hz, 1H), 7.97 (d, J = 8.4 Hz, 1H), 4.11 (s, 3H), 2.80 (s, 3H). LC-MS (ESI, m/z): Calcd for 
C13H10ClN2O2 ([M+H]+) 261.04, found: 261.00. 
 
3.11. Methyl 2-(bromomethyl)-4-chloro-6-cyanoquinoline-3-carboxylate (10) 
 
A light yellow solid, mp 108.5-109.9 °C. 1H NMR (600 MHz, CDCl3): δ 8.67 (d, J = 1.8 Hz, 
1H), 8.19 (d, J = 8.4 Hz, 1H), 7.98 (dd, J = 8.4, 1.8 Hz, 1H), 4.79 (s, 2H), 4.10 (s, 3H). LC-MS 
(ESI, m/z): Calcd for C13H9BrClN2O2 ([M+H]+) 340.94, found: 341.10. 
 
3.12. 9-Chloro-2-ethyl-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-b]quinoline-7-carbonitrile (11) 
 
A white solid, mp 195.5-196.1 °C. 1H NMR (600 MHz, CDCl3): δ 8.84 (d, J = 1.2 Hz, 1H), 8.24 
(d, J = 9.0 Hz, 1H), 8.00 (dd, J = 9.0, 1.2 Hz, 1H), 4.58 (s, 2H), 3.78 (q, J = 7.2 Hz, 2H), 1.35 (t, 
J = 7.2 Hz, 3H). HRMS (ESI, m/z): Calcd for C14H11ClN3O ([M+H]+) 272.0585, found: 
272.0585. 
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3.13. 9-((3-Chloro-4-methoxybenzyl)amino)-2-ethyl-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-
b]quinoline-7-carbonitrile (12) 
 
A white solid, mp 205.4-206.6 °C. 1H NMR (400 MHz, CD3Cl): δ 8.63 (t, J = 5.6 Hz, 1H), 8.58 
(s, 1H), 8.00 (d, J = 8.8 Hz, 1H), 7.80 (dd, J = 8.8, 1.6 Hz, 1H), 7.48 (d, J = 1.6 Hz, 1H), 7.36 
(dd, J = 8.4, 1.6 Hz, 1H), 7.02 (d, J = 8.4 Hz, 1H), 4.99 (d, J = 5.6 Hz, 2H), 4.44 (s, 2H), 3.96 (s, 
3H), 3.69 (q, J = 7.2Hz, 2H), 1.33 (t, J = 7.2 Hz, 3H). HRMS (ESI, m/z): Calcd for 
C22H20ClN4O2 ([M+H]+) 407.1275, found: 407.1273. 
 
3.14. 9-((3-Chloro-4-hydroxybenzyl)amino)-2-ethyl-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-
b]quinoline-7-carbonitrile (13) 
 
To a stirred solution of compound 12 (25 mg, 0.061 mmol) in CH2Cl2 (2 mL), BBr3 (30 μL, 0.3 
mmol) was added slowly at 0 ºC, and the reaction was continued at 0 ºC for 20 h. The reaction 
mixture was poured into ice water (5 mL), and then CH2Cl2 was removed under reduced 
pressure. The resulted aqueous solution was extracted with EtOAc (3 × 10 mL), and the 
combined organic layer was washed with water, brine, dried over anhydrous Na2SO4 and filtered. 
The organic solution was evaporated under vacuum, and the resulted crude product was purified 
by silica gel column chromatography with CH2Cl2/MeOH (100:1 to 25:1) as eluent to afford 13 
as a light yellow solid (5 mg, 20%), mp 185.1-186.4 °C. 1H NMR (400 MHz, DMSO-d6): δ 9.09 
(br s, 1H), 8.53 (m, 1H). 8.09 (d, J = 8.4 Hz, 1H), 8.00 (d, J = 8.4 Hz, 1H), 7.47 (d, J = 2.0 Hz, 
1H), 7.26 (dd, J = 8.4, 2.0 Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 5.40 (d, J = 4.8 Hz, 2H), 4.56 (s, 
2H), 3.64 (q, J = 7.2 Hz, 2H), 3.48 (br s, 1H), 1.30 (t, J = 7.2 Hz, 3H). 13C NMR (150 MHz, 
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DMSO-d6): δ 166.70, 165.95, 152.30, 151.31, 149.50, 131.34, 131.14, 130.74, 130.00, 129.06, 
127.26, 119.44, 118.95, 118.51, 116.67, 106.06, 104.16, 50.23, 48.70, 36.30, 12.98. HRMS (ESI, 
m/z): Calcd for C21H18ClN4O2 ([M+H]+) 393.1118, found: 393.1117. 
 
3.15. 2-Acetyl-10-((3-chloro-4-[11C]methoxybenzyl)amino)-1,2,3,4-
tetrahydrobenzo[b][1,6]naphthyridine-8-carbonitrile ([11C]5) and 9-((3-chloro-4-
[11C]methoxybenzyl)amino)-2-ethyl-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-b]quinoline-7-
carbonitrile ([11C]12) 
 
[11C]CO2 was produced by the 14N(p,α)11C nuclear reaction in the small volume (9.5 cm3) 
aluminum gas target provided with the Siemens RDS-111 Eclipse cyclotron. The target gas 
consisted of 1% oxygen in nitrogen purchased as a specialty gas from Praxair, Indianapolis, IN. 
Typical irradiations used for the development were 58 µA beam current and 15 min on target. 
The production run produced approximately 25.9 GBq of [11C]CO2 at EOB. Desmethylated 
precursor 6 or 13 (0.1-0.3 mg) was dissolved in CH3CN (300 µL). To this solution was added 
aqueous NaOH (2 N, 2 µL). The mixture was transferred to a small reaction vial. No-carrier-
added (high molar activity) [11C]CH3OTf that was produced by the gas-phase production method 
(Mock et al., 1999) within 12 min from [11C]CO2 through [11C]CH4 and [11C]CH3Br with silver 
triflate (AgOTf) column was passed into the reaction vial at room temperature (RT) until 
radioactivity reached a maximum (2 min), and then the reaction vial was isolated and heated at 
80 °C for 3 min. The contents of the reaction vial were diluted with aqueous NaHCO3 (0.1 M, 1 
mL). The reaction vial was connected to a 3 mL HPLC injection loop. The labeled product 
mixture solution was injected onto the semi-preparative HPLC column for purification. The 
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product fraction was collected in a recovery vial containing 30 mL water. The diluted tracer 
solution was then passed through a C-18 Sep-Pak Light cartridge, and washed with water (3 × 10 
mL). The cartridge was eluted with EtOH (3 × 0.4 mL) to release the labeled product, followed 
by saline (10-11 mL). The eluted product was then sterile-filtered through a Millex-FG 0.2 µm 
membrane into a sterile vial. Total radioactivity was assayed and total volume (10-11 mL) was 
noted for tracer dose dispensing. The overall synthesis time including HPLC-SPE purification 
and reformulation was 35-40 min from EOB. The decay corrected radiochemical yield was 40-
50%. Retention times (tR) in the analytical RP-HPLC system were: tR 6 = 3.24 min, tR 5 = 4.21 
min, and tR [11C]5 = 4.30 min; and tR 13 = 3.33 min, tR 12 = 5.52 min, and tR [11C]12 = 5.64 min. 
Retention times in the semi-preparative RP-HPLC system were: tR 6 = 5.51 min, tR 5 = 7.07 min, 
and tR [11C]5 = 7.12 min; and tR 13 = 3.89 min, tR 12 = 6.88 min, and tR [11C]12 = 6.93 min. 
 
 
4. Conclusion 
 
In summary, multiple step synthetic routes with reasonable yields have been developed to 
produce the precursors 6 and 13, the reference standards 5 and 12, and the target PET 
radiotracers [11C]5 and [11C]12. The radiosynthesis employed [11C]CH3OTf for O-11C-
methylation at the phenyl hydroxyl position of the precursor, followed by product purification 
and isolation by a semi-preparative RP-HPLC combined with SPE. [11C]5 and [11C]12 were 
obtained in high radiochemical yield, and high radiochemical purity, with a reasonably short 
overall synthesis time, and high molar activity. Two new carbon-11 labeled potent and selective 
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PDE5 inhibitors have been successfully radiosynthesized. This will facilitate studies to evaluate 
[11C]5 and [11C]12 as new potential PET agents for imaging of PDE5 in AD.    
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Figure and Scheme Legends 
 
Figure 1. PET PDE5 radioligands. 
 
Figure 2. A representative analytical RP-HPLC chromatographic profile for the radiotracers 
[11C]5 and [11C]12: (A) Radio-HPLC trace for [11C]5 and (B) UV-HPLC trace for [11C]5; (C) 
Radio-HPLC trace for [11C]12 and (D) UV-HPLC trace for [11C]12. Analytical RP-HPLC 
conditions were a Prodigy (Phenomenex) 5 µm C-18 column, 4.6 × 250 mm; mobile phase 65% 
CH3CN/35% 4.0 mM CH3COONa; flow rate 1.0 mL/min; UV (254 nm) and γ-ray (PIN diode) 
flow detectors.     
 
Scheme 1. Synthesis of the reference standard (5) and precursor (6). Conditions: (i) CuCN, N-
methyl-2-pyrrolidone (NMP), 200 ºC; (ii) KOH, EtOH, H2O, 60 ºC; (iii) 1-acetylpiperidin-4-one, 
POCl3, 60 ºC; (iv) 1, N,N-diisopropylethylamine (DIPEA), n-propanol, reflux; (v) BBr3, CH2Cl2, 
0 ºC. 
 
Scheme 2. Synthesis of the reference standard (12) and precursor (13). Conditions: (i) 
triphosgene, 1,4-dioxane, 90 ºC; (ii) NaH, methyl acetoacetate, dimethylamine (DMA), 90 ºC; 
(iii) POCl3, 110 ºC; (iv) 2,2’-azobis(2-methylpropionitrile), N-bromosuccinimide (NBS), CCl4, 
reflux; (v) EtNH2, EtOH, THF, 78 ºC; (vi) 1, DIPEA, n-propanol, 90 ºC, (vii) BBr3, CH2Cl2, 0 
ºC. 
 
Scheme 3. Synthesis of the radiotracers ([11C]5) and ([11C]12).  
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Figure 2. 
 
A.  Analytical radioactive HPLC trace for [11C]5, Retention time (tR) = 4.30 min  
 
B. Analytical UV HPLC trace for [11C]5, tR = 4.21 min 
 
C. Analytical radioactive HPLC trace for [11C]12, tR = 5.64 min 
 
D. Analytical UV HPLC trace for [11C]12, tR = 5.52 min 
 
  
m
V
0.00
500.00
1000.00
Minutes
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
AU
0.00
0.10
Minutes
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
m
V
0.00
100.00
200.00
Minutes
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
A
U
0.000
0.002
0.004
Minutes
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
 25 
Scheme 1. 
 
Br
O
O
NH2
NC
O
O
NH2
i ii
NC
OH
O
NH2
iii
NC
N
Cl
N
O
NC
N
NH
N
O
Cl
O
NC
N
NH
N
O
Cl
OH
iv
v
2, 49% 3, 85% 4, 17%
5, 45%6, 30%
O O
Cl
NH2 NH2
.
HCl
1, 76%
SO2Cl2, HOAc/Et2O, 25 
oC
(4-Methoxyphenyl)methanamine
Methyl 2-amino-5-bromobenzoate
 
  
 26 
Scheme 2. 
 
NC
N
H
O
O
O
NC
N
H
O
O
O
NC
N
O
OCl
NC
N
O
OCl
Br
NC
N
Cl
N
O
NC
N
NH
N
O
Cl
O
NC
N
NH
N
O
Cl
OH
i ii iii
iv
vvi
vii
7, 86% 8, 49% 9, 28%
10, 40%11, 26%
12, 62%
NC
OH
O
NH2
3
13, 20%  
  
 27 
Scheme 3. 
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